You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 47 No. 12, December 1990 TABLE OF CONTENTS
  Archives
  •  Online Features
  ARTICLE
 This Article
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal

Clinical and positron emission tomographic studies in the 'extrapyramidal syndrome' of dementia of the Alzheimer type

P. J. Tyrrell, G. V. Sawle, V. Ibanez, P. M. Bloomfield, K. L. Leenders, R. S. Frackowiak and M. N. Rossor
Medical Research Council Cyclotron Unit, Hammersmith Hospital, London, England.

Extrapyramidal signs, particularly rigidity and tremor, have been reported in a proportion of patients with dementia of the Alzheimer type. To test the hypothesis that these extrapyramidal signs are similar clinically and neurochemically to the extrapyramidal signs of Parkinson's disease, a group of 20 patients satisfying clinical criteria for probable Alzheimer's disease were studied and assessed clinically for the presence of rigidity, tremor, and bradykinesia. In those patients with extrapyramidal signs, qualitative differences were observed between the signs in these patients and in subjects with Parkinson's disease. Fifteen of 20 patients underwent fluoro-18-dopa scans, which showed no significant difference in fluoro-18-dopa uptake into the caudate and putamen between normal subjects and the rigid and nonrigid patients with Alzheimer's disease, in contrast to the marked reduction in fluoro-18-dopa uptake into the putamen that is observed in Parkinson's disease. This provides clinical and in vivo neurochemical support for the hypothesis that extranigral factors may be involved in the pathogenesis of rigidity in Alzheimer's disease.

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Functional pharmacology in human brain.
Raiteri
Pharmacol. Rev. 2006;58:162-193.
ABSTRACT | FULL TEXT  

Motor signs predict poor outcomes in Alzheimer disease
Scarmeas et al.
Neurology 2005;64:1696-1703.
ABSTRACT | FULL TEXT  

Motor signs during the course of Alzheimer disease
Scarmeas et al.
Neurology 2004;63:975-982.
ABSTRACT | FULL TEXT  

Cholinergic Drugs for Alzheimer's Disease Enhance in Vitro Dopamine Release
Zhang et al.
Mol. Pharmacol. 2004;66:538-544.
ABSTRACT | FULL TEXT  

Striatal dopamine transporter and extrapyramidal symptoms in frontotemporal dementia
Rinne et al.
Neurology 2002;58:1489-1493.
ABSTRACT | FULL TEXT  

Parkinson Disease Neuropathology: Later-Developing Dementia and Loss of the Levodopa Response
Apaydin et al.
Arch Neurol 2002;59:102-112.
ABSTRACT | FULL TEXT  

Dementia With Lewy Bodies Studied With Positron Emission Tomography
Cordery et al.
Arch Neurol 2001;58:505-508.
ABSTRACT | FULL TEXT  

PET shows that striatal dopamine D1 and D2 receptors are differentially affected in AD
Kemppainen et al.
Neurology 2000;55:205-209.
ABSTRACT | FULL TEXT  

Progressive frontal gait disturbance with atypical Alzheimer's disease and corticobasal degeneration
Rossor et al.
J. Neurol. Neurosurg. Psychiatry 1999;67:345-352.
ABSTRACT | FULL TEXT  

Striatal dopaminergic markers in dementia with Lewy bodies, Alzheimer's and Parkinson's diseases: rostrocaudal distribution
Piggott et al.
Brain 1999;122:1449-1468.
ABSTRACT | FULL TEXT  

The Depressions of Alzheimer's Disease: Sorting, Pharmacotherapy, and Clinical Advice
Knesper
J Geriatr Psychiatry Neurol 1995;8:S40-S51.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1990 American Medical Association. All Rights Reserved.